China
HXCORMED is a Chinese national high-tech enterprise founded in 2016 focusing on the research and development of high-end innovative medical devices such as mechanical circulation assist systems. The company's flagship product, the Corheart 6 Left Ventricular Assist System, is an implantable circulatory support system for the treatment of end-stage heart failure. Its miniaturized design makes it suitable for adult and pediatric patients with a body surface area larger than 1.2 m2.
In July 2023, HXCORMED received Chinese NMPA approval to deliver the Corheart 6 into the Chinese market. With over 200 patients implanted, the device has demonstrated excellent performance in terms of anti-infection, reliability, patient recovery, reduced adverse events, and improved hemocompatibility.
The company has applied for approximately 200 patents and has seen significant success in R&D, reflected in three rounds of financing over three consecutive years, including the recent CNY200.00M Series C investment in April 2023. This investment was led by Loyal Valley Capital and Greenwoods Investment.
HXCORMED has established itself as an innovative and promising player in the manufacturing industry, with its groundbreaking advancements in artificial heart technology attracting strong interest from both investors and the market.
